Misetionamide (GP-2250)
Ovarian Cancer, Pancreatic Cancer
Phase 1b/2aActive
Key Facts
Indication
Ovarian Cancer, Pancreatic Cancer
Phase
Phase 1b/2a
Status
Active
Company
About Persevere Therapeutics
Persevere Therapeutics, founded in 2019 and based in Cambridge, USA, is a private, clinical-stage biotech focused on oncology. Its lead candidate, misetionamide, is a first-in-class small molecule with a dual mechanism inhibiting c-MYC and NFκB, disrupting cancer cell energy metabolism and proliferation. The company has advanced misetionamide into Phase 1b/2a clinical trials and has secured seed financing to support development in ovarian and pancreatic cancers. Persevere's approach leverages a tumor-type agnostic, cancer cell-selective platform with potential for combination therapies.
View full company profile